Mazdutide Dosage, half-life & reference guide
Also known as IBI362 · LY3305677 · Xinermei
A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved. In the phase 3 GLORY-1 trial, people lost about 11% (4 mg) and 14% (6 mg) of their body weight at 48 weeks, and a 9 mg dose averaged about 17% at 60 weeks in GLORY-2.
- Studied range
- 2–6 mgstarting dose 2 mg
- How often
- Weekly
- Half-life
- ~10 days
- Evidence
- ●●●
Established - Route
- SubQ injection
Studied in research — not a recommendation.
How it works.
Once-weekly GLP-1 and glucagon receptor dual agonist built on oxyntomodulin, a gut hormone that acts on both receptors, with a C20 fatty-acid side chain that stretches its half-life to about 10 days. The GLP-1 arm curbs appetite; the glucagon arm adds energy expenditure (shown in mice). Developed by Innovent with Eli Lilly and approved in China in 2025 for weight management and type 2 diabetes. Its label steps the dose up every 4 weeks from 2 mg, and GI side effects come mostly during those step-ups.
Commonly reported: Strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few.
Half-life & active level
The half-life of Mazdutide is ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes).
Here's how a typical Mazdutide schedule accumulates over four weeks (one-compartment estimate).
An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.
Week by week.
What to expect in the first 8 weeks
- Onset
- Days–2 weeks
- Peak effect
- 48–60 weeks
- Duration
- Ongoing
Day 1–28 · 2 mgRCT
Appetite first, scale later
You're on 2 mg, the label's run-in for weeks 1 to 4. Commonly reported: appetite dropping within days, with nausea most likely in the day or two after the injection. In the phase 3 trial, GI side effects came mostly during the step-ups and eased once the dose held steady.
The science
The Chinese label (Xinermei, 2025) starts everyone at 2 mg once weekly for 4 weeks, then 4 mg, and GLORY-1 used the same ramp. GI side effects were reported by 62.6% on 4 mg and 79.7% on 6 mg vs 20.0% on placebo, mostly mild and short-lived, and fell markedly in the maintenance phase; two people (1.0%) on 4 mg stopped because of them (Ji 2025; label).
Sources- Ji et al. (GLORY-1) (2025)
- Xinermei label (China) (2025)
Updated Oct 2026
Day 29–56 · 4 mgRCT
A maintenance dose, not just a step
You're at 4 mg, which the label counts as a maintenance dose in its own right. Commonly reported: a few days of nausea after the step-up, then steadier appetite control. In GLORY-1, people on 4 mg averaged about 10% weight loss by week 32.
The science
GLORY-1 (Ji 2025, NEJM; 610 adults with a BMI of 28 or more, or 24 or more with a weight-related condition): the 4 mg arm (2 mg for 4 weeks, then 4 mg) reached −10.09% at week 32 and −11.00% at week 48, vs +0.45% and +0.30% on placebo (treatment-policy estimand). The label lists 4 mg and 6 mg as maintenance doses and allows stepping back from 6 to 4 mg.
Sources- Ji et al. (GLORY-1) (2025)
- Xinermei label (China) (2025)
Updated Oct 2026
Any dayRCT
What Mazdutide is built on
A full phase 3 program in China: GLORY-1 and GLORY-2 for weight, DREAMS-1 and DREAMS-2 for type 2 diabetes, behind its 2025 approvals there. It isn't FDA-approved; Lilly has tested higher doses in US trials.
The science
Developed by Innovent with Eli Lilly (Shirley 2025). GLORY-1 (Ji 2025, NEJM) and GLORY-2 (Gao 2026, JAMA) tested weight loss; DREAMS-1 (Zhu 2026, Nature) and DREAMS-2 (Guo 2026, Nature) found larger HbA1c and weight drops than placebo and than dulaglutide 1.5 mg in type 2 diabetes. In a US phase 2 trial of doses up to 16 mg, 16 mg reached −18.1% at 32 weeks, and 20% of that group stopped for side effects, mostly GI (Hsia 2026).
Sources- Shirley (2025)
- Ji et al. (GLORY-1) (2025)
- Gao et al. (GLORY-2) (2026)
- Zhu et al. (DREAMS-1) (2026)
- Guo et al. (DREAMS-2) (2026)
- Hsia et al. (2026)
Updated Oct 2026
With BPC-157Community
Why people add BPC-157 to Mazdutide
GI side effects come with each step-up, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.
The science
BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside mazdutide or any GLP-1 drug; the pairing comes from community reports.
Sources- Sikiric et al. (2018)
Updated Oct 2026
After week 8
Day 57–224 · 4 mgRCT
Holding at 4 mg
Staying at 4 mg is one of the label's two maintenance options. In GLORY-1 the 4 mg group averaged about 11% loss at 48 weeks, with about a third losing 15% or more, and with fewer GI side effects than 6 mg.
The science
GLORY-1 4 mg arm: −11.00% at week 48 vs +0.30% on placebo, and 35.7% reached at least 15% loss vs 2.0% (Ji 2025). In the label's safety table, nausea affected 32.5% on 4 mg vs 50.5% on 6 mg, and vomiting 26.1% vs 43.1% (placebo 5.9% and 2.9%).
Sources- Ji et al. (GLORY-1) (2025)
- Xinermei label (China) (2025)
Updated Oct 2026
Day 57–224 · 6 mgRCT
The top labelled dose
You're at 6 mg, the highest dose on the label. In GLORY-1 the 6 mg group averaged about 12.5% loss by week 32 and 14% by week 48, and half reached 15% or more. GI side effects are more common at 6 mg, and the label allows stepping back to 4 mg.
The science
GLORY-1 6 mg arm (2 → 4 → 6 mg, 4 weeks per step): −12.55% at week 32 and −14.01% at week 48 vs +0.30% on placebo; 49.5% reached at least 15% loss (Ji 2025). Label safety table: nausea 50.5%, vomiting 43.1% and diarrhea 38.6% at 6 mg (placebo 5.9%, 2.9%, 6.3%). Resting heart rate averaged 2.6 beats per minute above baseline at week 48 on mazdutide, with no rise on placebo. A 9 mg dose, above the label, averaged −16.65% at 60 weeks in the phase 3 GLORY-2 trial, with vomiting in 53.1% (Gao 2026).
Sources- Ji et al. (GLORY-1) (2025)
- Xinermei label (China) (2025)
- Gao et al. (GLORY-2) (2026)
Updated Oct 2026
Day 225–336RCT
Weeks 32 to 48: still moving, more slowly
Between weeks 32 and 48 of GLORY-1, average weight kept falling at both doses, more slowly than at the start. Waist size came down by about 9 to 11 cm over the 48 weeks.
The science
GLORY-1 (treatment-policy): −10.09% → −11.00% (4 mg) and −12.55% → −14.01% (6 mg) from week 32 to week 48 (Ji 2025). Label table (48 weeks, mITT): waist −9.1 cm (4 mg) and −10.7 cm (6 mg) vs −1.4 cm on placebo; systolic blood pressure −7.3 and −9.9 vs −2.1 mmHg; serum uric acid fell 36.7 µmol/L across both doses vs a 7.9 µmol/L rise on placebo.
Sources- Ji et al. (GLORY-1) (2025)
- Xinermei label (China) (2025)
Updated Oct 2026
Day 337+Clinical
A maintenance medication, not a course
Worth knowing before you stop: with other GLP-1 drugs, coming off usually means regaining most of the loss, about 10 kg in the first year and back to baseline in about a year and a half. Mazdutide hasn't been tested in a stopping trial, so this is the class pattern. Continue, taper or stop is a call for you and your clinician.
The science
A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). No withdrawal trial of mazdutide has been published, so this is class-level framing.
Sources- West et al. (2026)
Updated Oct 2026
Day 1 is the day you start it.
Phase 3 trials (GLORY-1, GLORY-2, DREAMS-1, DREAMS-2) and the Chinese label (Xinermei, NMPA 2025). Not FDA-approved.
Clinical trial data
Mixing and a typical run.
Example numbers
Reconstitution example
Reconstitute a 10 mg vial of Mazdutide with 2 mL of bacteriostatic water and a 2 mg dose is 40 units on a U-100 syringe, about 5 doses per vial.
- Vial
- 10 mg
- Water
- 2 mL
- Amount
- 2 mg
Draw to40 units
0.5 mL insulin syringe · 50 units
Run notes
- Cycle
- Used continuously, once weekly, in its trials and label. Per the label, a dose 1 to 3 weeks late (2 to 4 weeks since the last one) restarts one dose step lower, and more than 3 weeks late restarts the 2 mg step. No trial has tested stopping it.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Once weekly SubQ (the label names the abdomen), any time of day, with or without food. The label allows moving the weekly day as long as doses stay at least 5 days (120 hours) apart. Steady state builds over about 4 weekly doses.
- Route
- SubQ injection
- Stacks
- BPC-157 (GI support)
Safety.
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal bloating
- Abdominal pain
- Injection site reaction
- Dizziness
- Acid reflux
Interactions
Per its label, GLP-1 drugs like mazdutide slow stomach emptying and may change how oral medicines are absorbed, so drugs with a narrow margin (such as warfarin) are monitored more closely. With insulin or a sulfonylurea, the label suggests lowering their dose to limit low blood sugar. In its interaction studies, the shifts in atorvastatin, digoxin, metformin and warfarin levels were not expected to matter clinically. It is a GLP-1 drug itself, so it is not stacked with another one. Discuss all your medicines with your clinician.
Safety notes
Mazdutide's Chinese label carries a boxed warning for thyroid C-cell tumors seen in rodents (whether this applies to people is unknown), and it is not used with a personal or family history of medullary thyroid carcinoma or MEN 2. In the GLORY-1 phase 3 trial, GI side effects affected 62.6% on 4 mg and 79.7% on 6 mg vs 20.0% on placebo, mostly mild and short-lived and concentrated in the step-ups; 1.0% stopped for side effects, the same as on placebo. Gallstones were reported in 2.0% vs 1.0%, one person had a mild gallstone-related pancreatitis, and resting heart rate was on average 2.6 beats per minute higher at week 48. The label carries the GLP-1 class cautions (pancreatitis, gallbladder disease, dehydration-related kidney injury, low blood sugar alongside insulin or sulfonylureas), asks people to report palpitations or a racing heart at rest, and advises stopping at least 3 months before a planned pregnancy because of its long half-life. These are label and trial findings to review with your clinician.
Goes with.
Questions people ask.
What is Mazdutide?
A once-weekly GLP-1 and glucagon dual agonist from Innovent and Eli Lilly, approved in China in 2025 for weight management (as Xinermei) and type 2 diabetes; it is not FDA-approved. In the phase 3 GLORY-1 trial, people lost about 11% (4 mg) and 14% (6 mg) of their body weight at 48 weeks, and a 9 mg dose averaged about 17% at 60 weeks in GLORY-2.
How is Mazdutide dosed in research?
The research range for Mazdutide is 2–6 mg, weekly, with a 2 mg starting dose. Studied in research — not a recommendation.
How long does Mazdutide last?
The half-life of Mazdutide is ~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes).
What do people report on Mazdutide?
Commonly reported on Mazdutide: strong appetite suppression and GI side effects after each step-up, much as with other weekly GLP-1s; user reports from outside China are still few.
Is Mazdutide safe?
The research basis for Mazdutide is established: clinical trials or FDA-approved use exists. Common side effects in the library: nausea, diarrhea, vomiting, abdominal bloating, abdominal pain, injection site reaction, dizziness and acid reflux.
What does Mazdutide stack with?
Common stacks for Mazdutide: BPC-157 (GI support).
Research.
Reference.
- Cadence
Weekly
- Half-life
~10 days
~10 days (Chinese label: the mean in people with obesity or overweight; about 8 days in type 2 diabetes)
- Research basis
●●●
EstablishedClinical trials or FDA-approved use exists
PepVault for iPhone
Track Mazdutide in PepVault
Log every dose, keep your vial and the doses left in it and watch its estimated active level. 7 days free on the yearly plan for new subscribers.
Reviewed How we check the library